Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
50 participants
OBSERVATIONAL
2025-09-27
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection.
3. To assess correlation of METTL-14 expression with disease free survival and overall survival.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia
NCT01273636
Endometrial Changes in Breast Cancer Women.
NCT05717634
Factors Affecting the Prognosis of Patients With Endometrial Cancer
NCT01886040
Endometrial Cancer International Database
NCT04787159
Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO)
NCT06632431
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
N6-methyladenosine (m6A)is the most abundant RNA modification in mammalian mRNA and has a crucial role in the occurrence and development of various diseases, particularly malignant tumors(3). Many factors were found to affect the prognosis of endometrial carcinoma, one of these factors is m6A RNA methylation(5). This modification is dynamic and reversible, and it is catalyzed by three main types of regulators(3). It has been reported that m6A methylation was performed via methyltransferase complex regulators composed of "writer," "eraser," and "reader"(6).
Methyltransferase like 14 (METTL14), a member of "writer", acts to regulate the occurrence of various cancers(7). In most tumors METTL14 acts as an antioncogene, regulating the RNA of genes that help the cell detect and repair DNA damage, acting as a protective mechanism against cancer. Reducing m6A mRNA may be due to METTL14 mutation. Reducing m6A mRNA levels in endometrial cancer cells could enhance cell proliferation and tumorigenicity in vitro and in vivo(8).The role of METTL14 as a risk factor in prognosis of endometrial carcinoma is still unknown.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
endometrial carcinoma
Observation
observation of METTL-14 prognosis
IHC
IHC of METTL-14
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observation
observation of METTL-14 prognosis
IHC
IHC of METTL-14
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Hystrectomy operation
2. Available full clinical data about patient (age, complaint, findings in clinical examination).
3. Full data about previous biopsy and radiology.
4. Full data about patient survival, disease progression and history of chemotherapy for three years.
Exclusion Criteria
2\. Cases with no available H\&E stained slides or formalin fixed paraffin embedded block.
3.D\&C.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Monica Ashraf Alfy
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AssuitU
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
prognosisendometrialcarcinoma
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.